Neuspera neuromodulation device hits “gold standard” in incontinence trial
Results from the Phase II pivotal incontinence trial saw 42% of patients being declared completely dry, and 82% seeing a reduction by half. The post Neuspera neuromodulation device hits “gold standard” in incontinence trial appeared first on Medical Device Network.
Results from the Phase II pivotal incontinence trial saw 42% of patients being declared completely dry, and 82% seeing a reduction by half.
The post Neuspera neuromodulation device hits “gold standard” in incontinence trial appeared first on Medical Device Network.
